Delektorskaia V V, Smirnova E A, Ponomareva M V, Pavlova T V, Pavlov I A
Arkh Patol. 2010 Jul-Aug;72(4):3-6.
Papillary thyroid cancer (PTC) was ascertained to be characterized by a significant expression of matrix metalloproteinases (MMP-2 and 9) and a TIMP-2 inhibitor and decreased TIMP-1 accumulation in the cytoplasm of tumor cells; at the same time a combination of high cytoplasmic MMP-9 expression with no TIMP-1, as well as triple positive co-expression of MMP-2, MMP-9, and TIMP-2 are poor immunohistochemical indicators. The results of the performed study suggest that the detection of the types of expression of MMP-9+/TIMP-1 and MMP-2+/MMP-9+/TIMP-2+ is associated with the possible progression of a tumor process and concurrent with poor clinical and morphological signs, such as the large size of the tumor, the presence of intravascular invasion and regional metastases, organ capsular invasion, and low ultrastructural tumor cell differentiation. Thus, changes in the tumor expression of the extracellular matrix enzymes MMR-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 along with the major clinical, morphological, and ultrastructural signs of the disease are important additional indicators for analyzing the malignant potential of PTC.
甲状腺乳头状癌（PTC）的特征是基质金属蛋白酶（MMP - 2和9）和TIMP - 2抑制剂有显著表达，且肿瘤细胞胞质中TIMP - 1积累减少；同时，高胞质MMP - 9表达且无TIMP - 1，以及MMP - 2、MMP - 9和TIMP - 2的三联阳性共表达是不良的免疫组化指标。所进行研究的结果表明，检测MMP - 9 + /TIMP - 1和MMP - 2 + /MMP - 9 + /TIMP - 2 +的表达类型与肿瘤进程的可能进展相关，并与不良的临床和形态学体征同时出现，如肿瘤体积大、存在血管内侵犯和区域转移、器官包膜侵犯以及肿瘤细胞超微结构分化低。因此，细胞外基质酶MMR - 2和MMP - 9及其抑制剂TIMP - 1和TIMP - 2的肿瘤表达变化以及该疾病的主要临床、形态学和超微结构体征是分析PTC恶性潜能的重要附加指标。
